Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.

@article{Orlowski2005Phase1T,
  title={Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.},
  author={Robert Z. Orlowski and Peter Michael Voorhees and Reynaldo A. Garcia and Melissa D Hall and Fred J Kudrik and Tammy Allred and Anandhi R Johri and Paul E. Jones and Anastasia Ivanova and Hendrik W van Deventer and Don Alexander Gabriel and Thomas Charles Shea and Beverly S. Mitchell and Julian Adams and D E Esseltine and Elizabeth G Trehu and Marie Green and Mary Jo Lehman and Susan Natoli and J. Michael Collins and Celeste M. Lindley and Elizabeth Claire Dees},
  journal={Blood},
  year={2005},
  volume={105 8},
  pages={3058-65}
}
Proteasome inhibitors, a novel class of chemotherapeutic agents, enhance the antitumor efficacy of anthracyclines in vitro and in vivo. We therefore sought to determine the maximum tolerated dose (MTD) and dose-limiting toxicities of bortezomib and pegylated liposomal doxorubicin (PegLD). Bortezomib was given on days 1, 4, 8, and 11 from 0.90 to 1.50 mg/m2 and PegLD on day 4 at 30 mg/m2 to 42 patients with advanced hematologic malignancies. Grade 3 or 4 toxicities in at least 10% of patients… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS